论文部分内容阅读
目的探讨冠状动脉内注射血小板GPⅡb/Ⅲa受体拮抗剂替罗非班对急性心肌梗死(AMI)急诊经皮冠状动脉介入(PCI)治疗患者冠脉内TIMI血流的影响。方法选择AMI行PCI患者80例,分为替罗非班组和对照组各40例。比较两组术后TIMI血流级别、住院期间及治疗2个月后主要心脏不良事件(MACE)发生率及出血情况。结果替罗非班组和对照组PCI术后TIMI 3级血流发生率分别为90.0%和55.0%,两组比较差异有统计学意义(P<0.05)。替罗非班组住院期间及治疗2个月后MACE的发生率分别为7.5%、35.0%,对照组则分别为10.0%、40.0%;两组比较差异有统计学意义(P均<0.05)。两组均无颅内出血等严重出血事件发生。结论替罗非班能明显改善AMI急诊PCI术后TIMI血流状况,降低AMI急诊PCI术后患者MACE发生率,且不增加出血事件。
Objective To investigate the effect of intracoronary injection of platelet GPⅡb / Ⅲa receptor antagonist tirofiban on intracoronary TIMI flow in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Methods Eighty patients with AMI who underwent PCI were divided into two groups: Tirofiban group and control group. TIMI grade, postoperative hospitalization and incidence of major cardiac adverse events (MACE) and bleeding after 2 months of treatment were compared between the two groups. Results Tirofiban group and control group TIMI grade 3 blood flow after PCI was 90.0% and 55.0%, respectively, with significant difference between the two groups (P <0.05). The incidences of MACE during hospitalization and 2 months after treatment were 7.5% and 35.0% respectively in the tirofiban group and 10.0% and 40.0% in the control group, respectively. There was significant difference between the two groups (all P <0.05). No severe intracranial hemorrhage and other bleeding occurred in both groups. Conclusion Tirofiban can significantly improve the status of TIMI flow in patients with AMI after PCI and reduce the incidence of MACE in patients with AMI after PCI, without increasing the incidence of bleeding.